Clinical Trial Update: Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of fludarabine, rituximab, and alemtuzumab in patients with chronic lymphocytic leukemia has completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)
• Fludarabine (Fludarabine)
• Rituxan (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B-cell Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2012-12-03